# Intense Treatment Regimen With Intravitreal Aflibercept Injection

> **NCT03594461** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Vitreous -Retina- Macula Consultants of New York** · enrollment: 30 (estimated)

## Conditions studied

- Neovascular Age-Related Macular Degeneration

## Interventions

- **DRUG:** Aflibercept Injection

## Key facts

- **NCT ID:** NCT03594461
- **Lead sponsor:** Vitreous -Retina- Macula Consultants of New York
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-09-11
- **Primary completion:** 2020-03
- **Final completion:** 2020-06
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2019-01-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03594461

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03594461, "Intense Treatment Regimen With Intravitreal Aflibercept Injection". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT03594461. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*